Access cutting-edge multiple sclerosis treatment through this clinical trial at a research site in Cullman. Study-provided care at no cost to qualified participants.
Access multiple sclerosis specialists in Cullman at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple sclerosis treatment provided free
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve
Sponsor: Sanofi
Check if you qualify for this multiple sclerosis clinical trial in Cullman, AL
If you're searching for multiple sclerosis treatment options in Cullman, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Cullman research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.